Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats metastatic non-squamous non-small cell lung cancer (NSCLC), with no epidermal…. Sold as Alimta, Pemetrexed For Injection, Pemetrexed, Pemfexy. Every FDA application for this active ingredient: 4 branded and 1 generic.
As of Nov 14, 2026, FDA lists 5 applications for Pemetrexed (sold as Alimta, Pemetrexed For Injection, Pemetrexed and others), first approved Aug 19, 2004, with 4 new uses approved and 2 published complete response letters.
First approved: Aug 19, 2004
Applications: 5
New uses approved: 4
Complete response letters: 2
Medicare spending, 2025: $37.6M
First approved in the EU: Sep 20, 2004
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
AlimtaDrugs with a new indication and a new dosage for the preoperative adjuvant treatment for non-squamous non- small cell lung cancer. · Eli Lilly Japan K.K. · Aug 28, 2024
Alimta, new approvalDrugs with a new additional indication and a new dosage in an additional dosage form (Alimta Injection 100 mg) indicated for the treatment of unresectable… · Eli Lilly Japan K.K. · May 20, 2009
Clinical Trials
519 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Lilly